Literature DB >> 31576015

ΔNp63α exerts antitumor functions in cervical squamous cell carcinoma.

Ying Zhou1, Hanyuan Liu2, Juan Wang2, Xiaolin Wang3, Lili Qian1, Fei Xu2, Weiguo Song2, Dabao Wu1, Zhen Shen1, Dingqing Feng4, Bin Ling4, Weihua Xiao3, Ge Shan5,6, Liang Chen7,8.   

Abstract

The molecular basis underlying the aggressive nature and excessive proliferation of cervical squamous cancer cell remains unclear. ΔNp63α is the predominant isotype of p63 expressed in the epithelia and regulates epithelial cell differentiation. The pro-/anti-tumor role of ΔNp63α in different kinds of solid tumors remains controversial and the precise molecular mechanisms are still elusive. In this study, we uncovered the molecular functions of ΔNp63α in cervical squamous cell carcinoma to clarify its roles as a tumor suppressor. We demonstrated that ΔNp63α suppressed cell migration, invasiveness, and tumor growth in SiHa and ME-180 cells with both in vivo and in vitro assays. Mechanistic investigation via RNA-sequencing and chromatin immunoprecipitation-sequencing revealed that ΔNp63α exerted its antitumor capacity via regulating the expression of a cohort of cell junction genes. Further, we showed that ZNF385B and CLDN1 were two direct ΔNp63α targets with significant relevance to cervical squamous cell carcinoma examined in cell cultures, tumor xenografts, and clinic tumors. We also demonstrated that ΔNp63α downregulated NFATC1 to reduce cisplatin resistance. These findings shed new lights on functions of ΔNp63α in tumors and providing novel insights in targeted therapy of cervical cancers.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31576015     DOI: 10.1038/s41388-019-1033-x

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  52 in total

1.  p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development.

Authors:  A Yang; R Schweitzer; D Sun; M Kaghad; N Walker; R T Bronson; C Tabin; A Sharpe; D Caput; C Crum; F McKeon
Journal:  Nature       Date:  1999-04-22       Impact factor: 49.962

2.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

Review 3.  Biology and immunology of cancer stem(-like) cells in head and neck cancer.

Authors:  Xu Qian; Chenming Ma; Xiaobo Nie; Jianxin Lu; Minoo Lenarz; Andreas M Kaufmann; Andreas E Albers
Journal:  Crit Rev Oncol Hematol       Date:  2015-04-09       Impact factor: 6.312

Review 4.  p63 in epithelial development.

Authors:  E Candi; R Cipollone; P Rivetti di Val Cervo; S Gonfloni; G Melino; R Knight
Journal:  Cell Mol Life Sci       Date:  2008-10       Impact factor: 9.261

5.  Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.

Authors:  P G Rose; B N Bundy; E B Watkins; J T Thigpen; G Deppe; M A Maiman; D L Clarke-Pearson; S Insalaco
Journal:  N Engl J Med       Date:  1999-04-15       Impact factor: 91.245

Review 6.  Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition.

Authors:  Lindsey E Minion; Krishnansu S Tewari
Journal:  Gynecol Oncol       Date:  2018-02-03       Impact factor: 5.482

Review 7.  Genomic landscape of human papillomavirus-associated cancers.

Authors:  Maria Rusan; Yvonne Y Li; Peter S Hammerman
Journal:  Clin Cancer Res       Date:  2015-03-16       Impact factor: 12.531

8.  Comparison of concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil versus cisplatin plus paclitaxel in patients with locally advanced cervical carcinoma.

Authors:  Eui-Sok Sol; Tae Sung Lee; Suk Bong Koh; Hun Kyu Oh; Gi Won Ye; Youn Seok Choi
Journal:  J Gynecol Oncol       Date:  2009-03-31       Impact factor: 4.401

9.  HPV-negative carcinoma of the uterine cervix: a distinct type of cervical cancer with poor prognosis.

Authors:  L Rodríguez-Carunchio; I Soveral; R D M Steenbergen; A Torné; S Martinez; P Fusté; J Pahisa; L Marimon; J Ordi; M del Pino
Journal:  BJOG       Date:  2014-09-17       Impact factor: 6.531

10.  Identification and functional characterization of two new transcriptional variants of the human p63 gene.

Authors:  Marina Mangiulli; Alessio Valletti; Mariano Francesco Caratozzolo; Apollonia Tullo; Elisabetta Sbisà; Graziano Pesole; Anna Maria D'Erchia
Journal:  Nucleic Acids Res       Date:  2009-08-21       Impact factor: 16.971

View more
  3 in total

1.  SYT7 acts as an oncogene and a potential therapeutic target and was regulated by ΔNp63α in HNSCC.

Authors:  You Fu; Guocai Tian; Zhiyuan Zhang; Xiao Yang
Journal:  Cancer Cell Int       Date:  2021-12-20       Impact factor: 5.722

2.  The TΑp63/BCL2 axis represents a novel mechanism of clinical aggressiveness in chronic lymphocytic leukemia.

Authors:  Stamatia Laidou; Dionysios Grigoriadis; Sofia Papanikolaou; Spyros Foutadakis; Stavroula Ntoufa; Maria Tsagiopoulou; Giannis Vatsellas; Achilles Anagnostopoulos; Anastasia Kouvatsi; Niki Stavroyianni; Fotis Psomopoulos; Antonios M Makris; Marios Agelopoulos; Dimitris Thanos; Anastasia Chatzidimitriou; Nikos Papakonstantinou; Kostas Stamatopoulos
Journal:  Blood Adv       Date:  2022-04-26

3.  lncRNA PART1 and MIR17HG as ΔNp63α direct targets regulate tumor progression of cervical squamous cell carcinoma.

Authors:  Hanyuan Liu; Chenchen Zhu; Zhihao Xu; Juan Wang; Lili Qian; Qingqing Zhou; Zhen Shen; Weidong Zhao; Weihua Xiao; Liang Chen; Ying Zhou
Journal:  Cancer Sci       Date:  2020-09-29       Impact factor: 6.716

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.